Well at least they are not going blow that big cash pile anytime soon!The drop in the iron price mid year was really a positive for Molly, forced them to face reality and cut overhead which has always been way to high.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling